NCT04918810 (GUIDE) is a Phase 2 clinical trial of Docetaxel intermittent in Castration Resistant Prostatic Cancer, sponsored by Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Who is sponsoring NCT04918810?

NCT04918810 is sponsored by Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

What drugs are being tested in NCT04918810?

Interventions in NCT04918810: Docetaxel intermittent.

What condition does NCT04918810 study?

NCT04918810 studies Castration Resistant Prostatic Cancer.

Is NCT04918810 still recruiting?

NCT04918810 is currently terminated. Last updated 22 November 2024.

Last reviewed 2024-11-22 · How we verify

NCT04918810: GUIDE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

Terminated Phase 2 Last updated 22 November 2024

What this trial tests

Phase 2 trial testing Docetaxel intermittent in Castration Resistant Prostatic Cancer in 6 participants. Terminated before completion.

Timeline

29 July 2022

Primary endpoint
1 November 2024

1 November 2024

Quick facts

Lead sponsor	Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	29 July 2022
Primary completion	1 November 2024
Estimated completion	1 November 2024
Sites	8 locations across Australia

Drugs / interventions tested

Docetaxel intermittent — full drug profile →

Conditions studied

Castration Resistant Prostatic Cancer — all drugs for Castration Resistant Prostatic Cancer →

Sponsor

Australian and New Zealand Urogenital and Prostate Cancer Trials Group — full company profile →

Who can join

18 and older, male only, with Castration Resistant Prostatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see if a prostate cancer marker in the blood (mGSTP1) can be used to guide chemotherapy treatment. Based on the level of this blood marker, some people may be able to have breaks in treatment rather than having chemotherapy continuously which is the current standard of care. This study will tell us if having these treatment breaks guided by mGSTP1 can improve how people feel during treatment while still treating the prostate cancer effectively. Docetaxel is a chemotherapy drug that is approved to treat prostate cancer and has been used for many years to treat prostate cancer like yours. Your doctor has already discussed this with you and you have both agreed that docetaxel is the best treatment for you to have at this time. You will have already started this chemotherapeutic treatment with docetaxel.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).
Conduit C, Mak B, Qu W, Lulio JD, et al · · 2022 · cited 2× · PMID 35465297 · DOI 10.1177/17588359221092486

Verify or expand the search:

Other Australian and New Zealand Urogenital and Prostate Cancer Trials Group trials

Trials by the same sponsor.

NCT06594926 — Working Out M0 Bipolar Androgen Therapy · Phase 2 · recruiting
NCT04419402 — Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer · Phase 2 · unknown
NCT03685448 — ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) · Phase 2 · completed
NCT03392428 — A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer · Phase 2 · completed
NCT03280667 — Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04918810 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Last refreshed: 22 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04918810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing